Advancing Precision: A Controllable Self-Synergistic Nanoplatform Initiating Pyroptosis-Based Immunogenic Cell Death

Weiji Qin1, Lei Qiao2, Qian Wang3

  • 1School of Life Sciences, Anhui Medical University, Hefei 230011, P. R. China.

ACS Nano
|January 3, 2024
PubMed

Insights

This study introduces a novel nanoplatform that enhances pyroptosis immunotherapy by amplifying reactive oxygen species (ROS) production. This approach effectively targets tumor microenvironment heterogeneity and suppresses tumor growth, offering a promising strategy for cancer treatment.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Therapy

Background:

  • Tumor microenvironment (TME) heterogeneity limits cancer treatment efficacy.
  • Pyroptosis-based immunogenic cell death (ICD) therapy shows promise but faces limitations due to single-stimulus dependency.
  • Developing synergistic and tumor-specific therapies is crucial for overcoming treatment resistance.

Purpose of the Study:

  • To design a synergistic nanoplatform for enhanced pyroptosis-based ICD therapy.
  • To overcome TME heterogeneity and improve antitumor effects.
  • To develop a highly specific and modulable cancer treatment strategy.

Main Methods:

  • Constructed a nanoplatform with a neutrophil membrane shell and a self-synergistic reactive oxygen species (ROS) supplier.
  • Utilized laser irradiation to trigger exogenous ROS generation and heat production.
  • Leveraged upregulated NAD(P)H:quinone oxidoreductase 1 to catalyze β-Lapachone for endogenous ROS amplification.

Main Results:

  • The nanoplatform demonstrated stealth properties and efficient tumor accumulation.
  • Amplified ROS production led to enhanced gasdermin E-mediated pyroptosis and ICD.
  • The treatment effectively eliminated primary tumors and suppressed distant tumors by re-educating the TME and promoting systemic immunity.

Conclusions:

  • The developed self-synergistic nanoplatform provides an effective strategy for pyroptosis-based ICD therapy.
  • This approach addresses TME heterogeneity and enhances antitumor immune responses.
  • The nanoplatform offers a durable method for targeted tumor inhibition and immune system redesign.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
923
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K